Video

Dr. Gafita on Sequencing 177Lu-PSMA-617 in mCRPC

Andrei Gafita, MD, discusses sequencing lutetium-177 PSMA-617 in metastatic castration-resistant prostate cancer.

Andrei Gafita, MD, Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University Munich in Germany, discusses sequencing lutetium-177 PSMA-617 (177Lu-PSMA-617) in metastatic castration-resistant prostate cancer (mCRPC).

Typically, men with prostate cancer are given androgen deprivation therapy (ADT) as initial treatment, says Gafita. However, the majority of patients will eventually progress on ADT.

In mCRPC, patients will likely receive chemotherapy such as docetaxel, anti-androgen agents such as abiraterone acetate (Zytiga) or enzalutamide (Xtandi), or radium-223 dichloride (Xofigo), says Gafita. Additionally, PARP inhibitors have also become available for patients with mCRPC who harbor homologous recombination repair gene mutations.

Despite this, many patients exhaust all available treatment modalities, says Gafita. As such, 177Lu-PSMA-617 may have utility in patients who have progressed on all conventional therapeutic options.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity